Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 703,054 shares of the medical equipment provider’s stock after purchasing an additional 6,465 shares during the period. Intuitive Surgical makes up 0.6% of DekaBank Deutsche Girozentrale’s investment portfolio, making the stock its 27th largest holding. DekaBank Deutsche Girozentrale’s holdings in Intuitive Surgical were worth $336,944,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ISRG. Ullmann Wealth Partners Group LLC increased its holdings in Intuitive Surgical by 1.6% during the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after acquiring an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC grew its position in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares during the last quarter. Daymark Wealth Partners LLC increased its stake in shares of Intuitive Surgical by 0.3% during the 3rd quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock worth $3,452,000 after purchasing an additional 24 shares in the last quarter. Indiana Trust & Investment Management CO raised its position in shares of Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 25 shares during the last quarter. Finally, Hoxton Planning & Management LLC lifted its stake in Intuitive Surgical by 4.9% in the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,458,979.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 52,192 shares of company stock worth $25,398,571 over the last ninety days. 0.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ISRG shares. Citigroup boosted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a report on Friday, October 18th. Truist Financial lifted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Morgan Stanley upped their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $511.27 on Friday. The stock has a 50-day simple moving average of $487.98 and a 200-day simple moving average of $442.67. The stock has a market capitalization of $182.10 billion, a P/E ratio of 82.20, a PEG ratio of 5.11 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $523.34.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.